中国生物制药今日盘中大涨5.09%，引起了市场的广泛关注。
消息面上，公司旗下北京泰德制药自主研发的1类新药TRD205，针对慢性术后神经病理性疼痛的II期临床试验取得积极数据，并获国家药品监督管理局药品审评中心纳入突破性治疗药物名单。该药物有望填补该适应症临床治疗空白，且因其仅作用于外周，可能避免中枢神经系统类药物的常见不良反应。
与此同时，国际投行摩根士丹利重申对中国生物制药的“增持”评级，目标价维持7.8港元。在计入公司与阿斯利康及葛兰素史克等达成的商业授权收入后，摩根士丹利上调了公司未来几年的每股基本盈利预测。此外，公司近期业务发展成果密集兑现，包括TQC3721海外授权阿斯利康总额最高达19亿美元，以及TQB3454的上市申请获受理，标志着其创新研发管线正进入集中收获期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.